Compare Global Payments Inc (GPN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Pfizer Inc — how do they compare? Global Payments Inc trades at $82.8 (market cap $21.46B), while Pfizer Inc trades at $27.69 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 7.4× Global Payments Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Pfizer Inc for 158 Days on average.
| GPN | PFE | |
|---|---|---|
Market Cap | $21.46B | $158.56B |
Volume | 1,482,600 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $94.83 | $29.02 |
52-Week Low | $62.47 | $23.67 |
Typical Hold Time | 50 Days | 158 Days |
Enterprise Value | $39.60B | $210.06B |
Dividend Yield | 1.23% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $81.08, down 0.87% with bearish technical signals and neutral oscillators. The company shows mixed fundamentals with a P/E of 38.43 and negative net income margin of -9.15%, though recent quarters beat EPS estimates. Revenue declined to $7.71B in 2025 from $10.1B in 2024, while debt-to-asset ratio rose to 41.57%. Positive developments include Genius platform expansion and Worldpay integration driving growth opportunities.
The stock faces headwinds from declining profitability and rising debt, but analyst consensus remains bullish with a $102.75 price target representing 27% upside. Key risks include competitive pressures and execution challenges with new initiatives. Institutional interest persists with recent position increases by HSBC and Bank of New York Mellon.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
